Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer by fernando | Feb 24, 2026 | Media Coverage
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens by fernando | Jan 6, 2026 | Media Coverage
Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer by fernando | Dec 18, 2025 | Media Coverage
